Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”

Detalles Bibliográficos
Autores principales: Webster, Christopher J., Woollett, Gillian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790339/
https://www.ncbi.nlm.nih.gov/pubmed/31372960
http://dx.doi.org/10.1007/s40259-019-00372-3
_version_ 1783458778051510272
author Webster, Christopher J.
Woollett, Gillian R.
author_facet Webster, Christopher J.
Woollett, Gillian R.
author_sort Webster, Christopher J.
collection PubMed
description
format Online
Article
Text
id pubmed-6790339
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-67903392019-10-17 Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?” Webster, Christopher J. Woollett, Gillian R. BioDrugs Letter to the Editor Springer International Publishing 2019-08-01 2019 /pmc/articles/PMC6790339/ /pubmed/31372960 http://dx.doi.org/10.1007/s40259-019-00372-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Webster, Christopher J.
Woollett, Gillian R.
Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
title Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
title_full Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
title_fullStr Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
title_full_unstemmed Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
title_short Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
title_sort comment on “analysis of pharmacokinetic and pharmacodynamic parameters in eu-versus us-licensed reference biological products: are in vivo bridging studies justified for biosimilar development?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790339/
https://www.ncbi.nlm.nih.gov/pubmed/31372960
http://dx.doi.org/10.1007/s40259-019-00372-3
work_keys_str_mv AT websterchristopherj commentonanalysisofpharmacokineticandpharmacodynamicparametersineuversususlicensedreferencebiologicalproductsareinvivobridgingstudiesjustifiedforbiosimilardevelopment
AT woollettgillianr commentonanalysisofpharmacokineticandpharmacodynamicparametersineuversususlicensedreferencebiologicalproductsareinvivobridgingstudiesjustifiedforbiosimilardevelopment

Ejemplares similares